As part of our commitment to accelerate breakthrough research through the All Together We Can campaign, PanCAN announces nearly $3 million in grants that support cutting-edge science and fill critical gaps in the pancreatic cancer funding landscape. 🔬 The four Catalyst Research Awards, totaling nearly $2 million, are aimed at harnessing the power of tumor tissue, blood samples and patient data to accelerate the development of new treatments for patients with metastatic pancreatic cancer. This unparalleled resource — collected from participants in the PanCAN Precision Promise adaptive clinical trial platform — fills a critical gap in the research landscape. We’re providing researchers the materials they need to identify biomarkers of treatment response and resistance that can be targeted for more effective therapies. The goal is to drive discovery, inform trial design and bring us closer to a future where precision medicine is a reality for every person faced with this disease. Data generated from the awards will be integrated into PanCAN’s SPARK Research Data Platform and made available for future use by the pancreatic cancer research community, multiplying the value of these projects. Our eight Research Recovery Grants, totaling $1 million, fill the gap to rescue science that was otherwise going to go unfunded due to federal funding uncertainties. We are strategically targeting a breadth of topics and scientists at various career stages. These grants support researchers as the field reaches a critical turning point: With more RAS-targeting therapies in the pipeline than ever before, our goal is to keep the momentum we need to deliver breakthroughs as soon as possible for patients and families facing this disease. Meet this year’s Catalyst Research Award and Research Recovery Grant recipients at 🔗 pcan.at/bs58394r.